ProThera receives $1.9M NIH grant for infant-assessment test research

PROVIDENCE – ProThera Biologics Inc. has been awarded a two-year $1.9 million Phase II grant from the National Institutes of Health to study the potential of a new test to assess prognosis of infants who have or might develop sepsis and necrotizing entercolitis, the company announced Wednesday. The Small Business Innovation Research Fast Track grant…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.